An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type.
To elucidate the role of catecholamines in attention deficit disorder, the authors conducted an open 8-week trial of L-tyrosine in 12 adults with attention deficit disorder, residual type. Eight showed marked to moderate clinical response in 2 weeks; at 6 weeks these eight developed tolerance, suggesting that L-tyrosine is not useful in attention deficit disorder, residual type.
Reimherr
F W
FW
Wender
P H
PH
Wood
D R
DR
Ward
M
M
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D014443:Tyrosine / Q000627:therapeutic use*
D014443:Tyrosine; D007980:Levodopa; D010649:Phenylalanine